Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Reese A Cosimi, Nahal Beik, David W Kubiak, Jennifer A Johnson, Reese A Cosimi, Nahal Beik, David W Kubiak, Jennifer A Johnson

Abstract

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections. Twenty-two manuscripts published between 2010 and 2016 met inclusion criteria. Mean clinical cure was 74% across 379 patients treated with ceftaroline for severe MRSA infections. Toxicities were infrequent. Ceftaroline treatment resulted in clinical and microbiologic cure for severe MRSA infections. Close monitoring of hematological parameters is necessary with prolonged courses of ceftaroline.

Keywords: bacteremia; ceftaroline; endocarditis; methicillin-resistant Staphylococcus aureus (MRSA); pneumonia..

References

    1. Teflaro [package insert] Saint Louis, MO: Forest Pharmaceuticals; 2016.
    1. Jorgenson MR, DePestel DD, Carver PL. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ann Pharmacother. 2011;45:1384–98.
    1. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother. 2013;57:734–44.
    1. Stryjewski ME, Jones RN, Corey GR. Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. Diagn Microbiol Infect Dis. 2015;81:183–8.
    1. Stevens DL, Bisno AL, Chambers HF et al. ; Infectious Diseases Society of America Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10–52.
    1. Vidaillac C, Leonard SN, Rybak MJ. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. Int J Antimicrob Agents. 2010;35:527–30.
    1. Ramani A, Udeani G, Evans J et al. . Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. J Chemother. 2014;26:229–34.
    1. Corey GR, Wilcox M, Talbot GH et al. . Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641–50.
    1. Naber CK. Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies. Clin Infect Dis. 2009;48(suppl 4):S231–7.
    1. Ho TT, Cadena J, Childs LM et al. . Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267–70.
    1. Lin JC, Aung G, Thomas A et al. . The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42–9.
    1. Polenakovik HM, Pleiman CM. Ceftaroline for meticillin-resistant Staphylococcus aureus bacteraemia: case series and review of the literature. Int J Antimicrob Agents. 2013;42:450–5.
    1. Fabre V, Ferrada M, Buckel WR, Avdic E, Cosgrove SE. Ceftaroline in combination with trimethoprim-sulfamethoxazole for salvage therapy of methicillin-resistant Staphylococcus aureus bacteremia and endocarditis. Open Forum Infect Dis. 2014;1:ofu046.
    1. Casapao AM, Davis SL, Barr VO et al. . Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541–6.
    1. Kuriakose SS, Rabbat M, Gallagher JC. Ceftaroline CSF concentrations in a patient with ventriculoperitoneal shunt-related meningitis. J Antimicrob Chemother. 2015;70:953–4.
    1. Balouch MA, Bajwa RJ, Hassoun A. Successful use of ceftaroline for the treatment of MRSA meningitis secondary to an infectious complication of lumbar spine surgery. J Antimicrob Chemother. 2015;70:624–5.
    1. Bucheit J, Collins R, Joshi P. Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy. Am J Health Syst Pharm. 2014;71:110–3.
    1. Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract (1995). 2015;43:144–9.
    1. Pasquale TR, Tan MJ, Trienski TL, File TM Jr. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother. 2015;27:29–34.
    1. Rand KH, Houck HJ. Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2004;48:2871–5.
    1. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother. 2004;53:530–2.
    1. Dhand A, Bayer AS, Pogliano J et al. . Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis. 2011;53:158–63.
    1. Rose WE, Schulz LT, Andes D et al. . Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity. Antimicrob Agents Chemother. 2012;56:5296–302.
    1. Baxi SM, Chan D, Jain V. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature. Infection. 2015;43:751–4.
    1. Sakoulas G, Moise PA, Casapao AM et al. . Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. Clin Ther. 2014;36:1317–33.
    1. Cunha BA, Gran A. Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy. Int J Antimicrob Agents. 2015;46:225–6.
    1. Sundaragiri PR, Vallabhajosyula S, Haddad TM, Esterbrooks DJ. Tricuspid and mitral endocarditis due to methicillin-resistant Staphylococcus aureus exhibiting vancomycin-creep phenomenon. BMJ Case Reports. 2015; doi:10.1136/bcr-2015–211974.
    1. Safety information. Ceftaroline (Teflaro) Silver Spring, MD: US Food and Drug Administration; 2015.
    1. Varada NL, Sakoulas G, Lei LR, Chua J. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin. Pharmacotherapy. 2015;35:608–12.
    1. LaVie KW, Anderson SW, O’Neal HR Jr et al. . Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2015;60:264–9.
    1. Jain R, Chan JD, Rogers L et al. . High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy. 2014;34:758–63.
    1. Furtek KJ, Kubiak DW, Barra M et al. . High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016;71:2010–3.
    1. Blumenthal K, Kuhlen JL, Weil AA et al. . Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort. J Allergy Clin Immunol Pract. 2016;4:740–6.
    1. Alm RA, McLaughlin RE, Kos VN et al. . Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective. J Antimicrob Chemother. 2014;69:2065–75.
    1. Long SW, Olsen RJ, Mehta SC et al. . PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2014;58:6668–74.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa